Abstract:Abstract Background Long‐term maintenance of synaptic adaptations, assessed by long‐term potentiation (LTP), relies on gene induction, and can be impaired by pathological forms of tau protein in Alzheimer’s disease and related dementias (ADRD). We have previously shown that alterations in activity‐dependent gene expression profiles present in tauopathy mice are normalized by LM11A‐31 (C31), a small molecule p75 neurotrophin receptor (NTR) signaling modulator. However, altered gene expression levels represent only part of the complexity of the activity‐regulated transcriptional program. Since neuronal stimulation regulates alternative splicing of a number of activity‐regulated transcripts, and its disruption is associated with dysfunctional changes in ADRD, we aim to identify potential alternative splicing events related to tau‐mediated synaptic dysfunction and whether such alterations are influenced by treatment with a p75 NTR modulator. Method PS19 (P301S) and wildtype mice were treated with vehicle (Veh) or C31 by oral gavage at 6 months of age for 3 consecutive months. Gene translation‐ and protein synthesis‐dependent synaptic plasticity was induced by applying three events of theta burst stimulation (TBS). RNA sequencing on stimulated [(+) TBS] slices was used to generate activity‐related profiles of alternative splicing events at the isoform level. Result We identified axon guidance, glutamatergic synapse, long‐term potentiation and calcium signaling KEGG pathways among the top significant pathways with isoforms down‐regulated in (+) TBS PS19 relative to (+) WT slices. This isoform downregulation was substantially mitigated in (+) TBS slices from PS19 mice treated with C31 (see figure). For example, CACNA1H‐202, a splice‐variant that encodes a voltage‐gated calcium channel protein required for proper synaptic function, is found among the splice variants down‐regulated in Veh and up‐regulated in C31‐treated (+) TBS PS19 slices. Conversely, Prickle2‐204 isoform, associated with the formation of glutamatergic synapses, is up‐regulated in Veh and down‐regulated in C31‐treated (+) TBS PS19 slices. Currently, we are validating and examining the roles of these key C31‐modulated isoforms in neuronal function and synaptic strength as candidate molecular mechanisms involved in activity‐related effects contributing to tau‐induced neurodegeneration. Conclusion We identified neuronal activity‐related mRNA isoform modulation by C31, indicating that p75NTR signaling might influence alternative splicing events that compromise synapse function in ADRD.

NAD+ - and EVA1-C-dependent reversal of neurological deficits is mediated by differential alternative RNA splicing in tauopathic animal models

Alzheimer’s Disease-Associated U1 Snrnp Splicing Dysfunction Causes Neuronal Hyperexcitability and Cognitive Impairment

Mechanistic insights into NAD synthase NMNAT chaperoning phosphorylated Tau from pathological aggregation

Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment

Long-read transcriptomic identification of synaptic adaptation to amyloid pathology in the App(NL-G-F) knock-in mouse model of the earliest phase of Alzheimer's disease

NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING

Mitochondrial small RNA alterations associated with increased lysosome activity in an Alzheimer's Disease Mouse Model uncovered by PANDORA-seq

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease

Neuronal stimulation‐regulated RNA splicing defects in tauopathies are corrected by treatment with a p75 NTR modulator

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer’s disease

APOER2 splicing repertoire in Alzheimer's disease: Insights from long-read RNA sequencing

A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons

Nicotinamide Mononucleotide Adenylyltransferase Uses Its NAD+ Substrate-Binding Site to Chaperone Phosphorylated Tau.

Exploring the Frontier: Antisense Long Non-Coding RNAs As Key Regulators in Alzheimer's Disease.

Dysregulation of RNA Splicing in Tauopathies.

NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS–STING

Comprehensive transcript-level analysis reveals transcriptional reprogramming during the progression of Alzheimer's disease

Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology.

Tip60's Novel RNA-Binding Function Modulates Alternative Splicing of Pre-mRNA Targets Implicated in Alzheimer's Disease

Spatial Expression of Long Non-Coding RNAs in Human Brains of Alzheimer's Disease